-
公开(公告)号:US07192962B2
公开(公告)日:2007-03-20
申请号:US10449650
申请日:2003-05-30
申请人: Vilas H. Dahanukar , Hoa N. Nguyen , Cecilia A. Orr , Funcheng Zhang , Ilia A. Zavialov , Kevin Klopfer , Jeffrey M. Skell , Albert W. Buchholz, Jr. , Craig D. Boyle
发明人: Vilas H. Dahanukar , Hoa N. Nguyen , Cecilia A. Orr , Funcheng Zhang , Ilia A. Zavialov , Kevin Klopfer , Jeffrey M. Skell , Albert W. Buchholz, Jr. , Craig D. Boyle
IPC分类号: A07D473/04 , A61K31/522 , A61P9/12 , A61P15/10
CPC分类号: C07D473/04
摘要: Crystalline polymorphs of 1-ethyl-3,7-dihydro-8-[(1R,2R) -(hydroxycyclopentyl)amino]-3-(2-hydroxyethyl)-7-[(3-bromo-4-methoxyphenyl)methyl]-1H-Purine-2,6-dione in Form 1 and Form 2, which exhibit x-ray powder diffraction profiles substantially the same as those shown in FIGS. 5 and 6, respectively, and which exhibit differential scanning calorimtery profiles substantially the same as those shown in FIGS. 2 and 4, respectively, and are represented by the formula: Pharmaceutical compositions comprising the polymorph Form 1 or 2 of Compound 13 and at least one excipient or carrier, and methods of using the polymorph Form 1 or 2 of Compound 13 to treat a variety of physiological disorders, such as erectile dysfunction.
摘要翻译: 1-乙基-3,7-二氢-8 - [(1R,2R) - (羟基环戊基)氨基] -3-(2-羟乙基)-7 - [(3-溴-4-甲氧基苯基)甲基] 形式1和形式2的-1H-嘌呤-2,6-二酮,其显示与图1和2所示的X-射线粉末衍射分布基本相同的X-射线粉末衍射分布。 分别示出了与图1和图2所示的相似的差示扫描量热分析图。 2和4,并且由下式表示:包含化合物13的多晶型物1或2和至少一种赋形剂或载体的药物组合物,以及使用化合物13的多晶型物1或2的方法来处理多种 的生理障碍,如勃起功能障碍。